A Non-Randomized, Open-Label, Parallel Group, Single-Dose Study to Compare the Pharmacokinetics of GBT440 in Subjects With Renal Impaired Function to Healthy Subjects
Latest Information Update: 26 Oct 2020
At a glance
- Drugs Voxelotor (Primary)
- Indications Hypoxia; Idiopathic pulmonary fibrosis; Liver disorders; Sickle cell anaemia
- Focus Pharmacokinetics
- Sponsors Global Blood Therapeutics
- 20 Oct 2020 Results of two studies ( NCT03161015 and NCT03114540) assessing pharmacokinetics of Voxelotor published in the Journal of Clinical Pharmacology
- 20 Feb 2018 Status changed from recruiting to completed.
- 23 May 2017 New trial record